Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

• Status: Completed
• Trial end date: 2020-06-26
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety, pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart failure of ischemic origin (NYHA 1-3).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardior Pharmaceuticals GmbH

Criteria

Inclusion Criteria:

• Stable heart failure of ischemic origin

Exclusion Criteria:

• Heart failure of non-ischemic origin (hypertensive heart disease, myocarditis, alcoholic cardiomyopathy and cardiac dysfunction due to rapid atrial fibrillation),